Alfuzosin: an α₁-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia

Bibliography

• POOL JL, KIRBY RS: Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia. Int. Urol. Nephrol. (2001) 33(3):407-412.
   PubMedGoogle Scholar
• KUMAR VL, DEWAN S: Alpha adrenergic blockers in the treatment of benign hyperplasia of the prostate. Int. Urol. Nephrol. (2000) 32(1):67-71.
   PubMedGoogle Scholar
• AUA PRACTICE GUIDELINES COMMITTEE: AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J. Urol. (2003) 170:530-547.
   PubMed Web of Science ®Google Scholar
• HIEBLE JP, RUFFOLO RR Jr: The use of alpha-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview. Pharmacol. Res. (1996) 33(3):145-160.
   PubMed Web of Science ®Google Scholar
• BASAR MM, ATAN A, OZERGIN O, YILDIZ M: The efficacy of alfuzosin treatment in patients with prostatism. Int. Urol. Nephrol. (2001) 33(3):493-497.
   PubMedGoogle Scholar
• ROEHRBORN CG, BARTSCH G, KIRBY R et al.: Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative international overview. Urology (2001) 58(5):642-650.
   PubMed Web of Science ®Google Scholar
• CHUTE CG, PANSER LA, GIRMAN CJ et al.: The prevalence of prostatism: a population-based survey of urinary symptoms. J. Urol. (1993) 150:85-89.
   PubMed Web of Science ®Google Scholar
• FURUYA S, KUMAMOTO Y, YOKOYAME E et al.: Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J. Urol. (1982) 128:836.
   PubMed Web of Science ®Google Scholar
• ANDERSSON KE: Prostatic and extraprostatic alpha-adrenoceptors-contributions to the lower urinary tract symptoms in benign prostatic hyperplasia. Scand. J. Urol. Nephrol (1996) 179:105.
   Google Scholar
• CHAPPLE CR: Alpha adrenoceptor antagonists in the year 2000: is there anything new. Curr. Opin. Urol. (2001) 11:9-16.
   PubMedGoogle Scholar
• DEBRUYNE FM: Alpha blockers: are all created equal? Urology (2000) 56(5 Suppl. 1):20-22.
   PubMed Web of Science ®Google Scholar
• HEIMBACH D, MULLER SC: [Treatment of benign prostatic hyperplasia with alpha 1-adrenoreceptor antagonists]. Urologe A. (1997) 36(1):18-34.
   PubMedGoogle Scholar
• NICKEL JC, HERSCHORN S, CORCOS J et al.: Canadian guidelines for the management of benign prostatic hyperplasia. Can. J. Urol. (2005) 12(3):2677-2683.
   PubMedGoogle Scholar
• DUTKIEWICS S: Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia. Int. Urol. Nephrol. (2001) 32(3):423-432.
   PubMedGoogle Scholar
• LOWE F: Alpha-1-adrenoceptor blockade in the treatment of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. (1999) 2(3):110-119.
   PubMed Web of Science ®Google Scholar
• ANDERSSON KE, LEPOR H, WYLLIE MG: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate (1997) 30(3):202-215.
   PubMed Web of Science ®Google Scholar
• LANGER SZ: History and nomenclature of alpha1-adrenoceptors. Eur. Urol. (1999) 36(Suppl. 1):2-6.
   Web of Science ®Google Scholar
• FAURE C, PIMOULE C, VALLANCIEN G, LANGER SZ, GRAHAM D: Identification of alpha 1-adrenoceptor subtypes present in the human prostate. Life Sci. (1994) 54(21):1595-1605.
   PubMed Web of Science ®Google Scholar
• NASU K, MORIYAMA N, KAWABE K et al.: Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br. J. Pharmacol. (1996) 119:797-803.
   PubMed Web of Science ®Google Scholar
• WYLLIE MG: Uroselectivity: end of the road? BJU Int. (2003) 92:141-142.
   PubMedGoogle Scholar
• MARTIN DJ, LLUEL P, GUILLOT E, COSTE A, JAMMES D, ANGEL I: Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J. Pharmacol. Exp. Ther. (1997) 282(1):228-235.
   PubMed Web of Science ®Google Scholar
• FLAVAHAN NA, VANHOUTTE PM: Alpha-adrenoceptor sub-classification in vascular smooth muscle. Trends Pharmacol. Sci. (1986) 7:347-349.
   Web of Science ®Google Scholar
• MURAMATSU I, OHMURA T, KIGOSHI S, HASHIMOTO S, OSHITA M: Pharmacological subclassification of alpha1-adrenoceptors in vascular smooth muscle. Br. J. Pharmacol. (1990) 99:197-201.
   PubMed Web of Science ®Google Scholar
• WALDEN PD, GERARDI C, LEPOR H: Localization and expression of the alpha 1A-1, alpha 1B and alpha 1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J. Urol. (1999) 161:635-640.
   PubMed Web of Science ®Google Scholar
• ROEHRBORN CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology (2001) 58(6 Suppl. 1):55-63.
   PubMed Web of Science ®Google Scholar
• ECKERT RE, SCHREIER U, ALLOUSSI S et al.: Zellulare Grndlage der dynamischen, infravesikalen Obstruktion im Rahmen der benignen Prostatahyperplasie: Rolle von Alpharezeptorenblockern und zyklischen. Nukleotiden. Akt Urol. (1998) 29:252-260.
   Google Scholar
• ECKERT RE, SCHREIER U, ALLOUSSI S et al.: Prostate selectivity of alpha-1-adrenoceptors. J. Urol. (1995) 233(Suppl. 4):233.
   Google Scholar
• MOTTET N, BRESSOLLE F, DELMAS V, ROBERT M, COSTA P: Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration. Eur. Urol. (2003) 44(1):101-105.
   PubMedGoogle Scholar
• BUZELIN JM, DELAUCHE-CAVALLIER MC, ROTH S, GEFFRIAUD-RICOUARD C, SANTONI JP: Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. Br. J. Urol. (1997) 79(6):898-904.
   PubMedGoogle Scholar
• BUZELIN JM, ROTH S, GEFFRIAUD-RICOUARD C, DELAUCHE-CAVALLIER MC: Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group. Eur. Urol. (1997) 31(2):190-198.
   PubMedGoogle Scholar
• LUKACS B, BLONDIN P, MACCARTHY C, DU BB, GRIPPON P, LASSALE C: Safety profile of 3 months’ therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy. Eur. Urol. (1996) 29(1):29-35.
   PubMed Web of Science ®Google Scholar
• LUKACS B, GRANGE JC, COMET D, MCCARTHY C: History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years. Eur. Urol. (2000) 37(2):183-190.
   PubMed Web of Science ®Google Scholar
• LUKACS B, GRANGE JC, MCCARTHY C, COMET D: Clinical uroselectivity: a 3-year follow-up in general practice. BPH Group in General Practice. Eur. Urol. (1998) 33(Suppl. 2):28-33.
   PubMedGoogle Scholar
• SANCHEZ-CHAPADO M, GUIL M, BADIELLA LI, FERNANDEZ-HERNANDO N, ALFARO V: The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. BJU Int. (2000) 86(4):432-438.
   PubMed Web of Science ®Google Scholar
• LUKACS B, GRANGE JC, COMET D, MCCARTHY C: Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice. Prostate Cancer Prostatic Dis. (1998) 1(5):276-283.
   PubMedGoogle Scholar
• HOFNER K, JONAS U: Alfuzosin: a clinically uroselective alpha1-blocker. World J. Urol. (2002) 19(6):405-412.
   PubMed Web of Science ®Google Scholar
• MCKEAGE K, PLOSKER GL: Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs (2002) 62(4):633-653.
   PubMed Web of Science ®Google Scholar
• VAN KERREBROECK P, JARDIN A, LAVAL KU, VAN CANGH P: Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur. Urol. (2000) 37(3):306-313.
   PubMedGoogle Scholar
• MCKEAGE K, PLOSKER GL: Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs (2002) 62(4):633-653.
   PubMed Web of Science ®Google Scholar
• SANOFI-SYNTHELABO CANADA INC: Xatral product monograph: alfuzosin hydrochloride prolonged-release tablets 10 mg. Revised December 2004.
   Google Scholar
• HANSEN BJ, MORTENSEN S, MENSINK HJ et al.: Comparison of the Danish Prostatic Symptom Score with the International Prostatic Symptom Score, the Madsen-Iversen and Boyarsky symptom indexes. ALFECH Study Group. Br. J. Urol. (1998) 81(1):36-41.
   PubMedGoogle Scholar
• CORCOS J, BEAULIEU S, DONOVAN J et al.: Quality of life assessment in men and women with urinary incontinence. J. Urol. (2002) 168:896-905.
   PubMed Web of Science ®Google Scholar
• O’LEARY MP, FOWLER FJ, LENDERKING WR et al.: A brief male sexual function inventory for urology. Urology (1995) 46:697-706.
   PubMed Web of Science ®Google Scholar
• MARKS LS, ROEHRBORN CG, GITTELMAN M, KIM D, FORREST J, JACOBS S: First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia. Urology (2003) 62(5):888-893.
   PubMedGoogle Scholar
• ROEHRBORN CG: Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology (2001) 58(6):953-959.
   PubMed Web of Science ®Google Scholar
• VAN KERREBROEC P, JARDIN A, VAN CANGH P, LAVAL KU, THE ALFORTI STUDY GROUP: Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. Eur. Urol. (2002) 41:54-61.
   PubMedGoogle Scholar
• ROEHRBORN CG, VAN KERREBROECK P, NORDLING J: Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int. (2003) 92(3):257-261.
   PubMed Web of Science ®Google Scholar
• LUKACS B, GRANGE JC, COMET D: One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice. Urology (2000) 55(4):540-546.
   PubMedGoogle Scholar
• LUKACS B, LEPLEGE A, THIBAULT P, JARDIN A: Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology (1996) 48(5):731-740.
   PubMed Web of Science ®Google Scholar
• EMBERTON M, ELHILALI M, MATZKIN H et al.: Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. Urology (2005) 66(2):316-322.
   PubMed Web of Science ®Google Scholar
• VAN MOORSELAAR RJ, HARTUNG R, EMBERTON M et al.: Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int. (2005) 95(4):603-608.
   PubMedGoogle Scholar
• ELHILALI M, EMBERTON M, MATZKIN H et al.: Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in real life practice. BJU Int. (In press).
   Google Scholar
• JACOBSEN SJ, JACOBSON DJ, GIRMAN CJ et al.: Natural history of prostatism: risk factors for acute urinary retention. J. Urol. (1997) 158(2):481-487.
   PubMed Web of Science ®Google Scholar
• GIRMAN CJ, EPSTEIN RS, JACOBSEN SJ et al.: Natural history of prostatism: Impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology (1994) 44:825-831.
   PubMed Web of Science ®Google Scholar
• SHAH T, PALIT V, BIYANI S, ELMASRY Y, PURI R, FLANNIGAN GM: Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. Eur. Urol. (2002) 42(4):329-332.
   PubMed Web of Science ®Google Scholar
• PICKARD R, EMBERTON M, NEAL DE: The management of men with acute urinary retention. National Prostatectomy Audit Steering Group. Br. J. Urol. (1998) 81(5):712-720.
   PubMedGoogle Scholar
• ANNEMANS L, CLEEMPUT I, LAMOTTE M, MCNEILL A, HARGREAVE T: The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis. BJU Int. (2005) 96(4):566-571.
   PubMedGoogle Scholar
• MCNEILL SA: Does acute urinary retention respond to alpha-blockers alone? Eur. Urol. (2001) 39 (Suppl. 6):7-12.
   PubMedGoogle Scholar
• SCHULMAN CC: Long-term aspects of medical treatment of BPH. Eur. Urol. (2001) 40(Suppl. 3):8-12.
   PubMedGoogle Scholar
• MCNEILL SA, HARGREAVE TB, ROEHRBORN CG: Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. Urology (2005) 65(1):83-89.
   PubMed Web of Science ®Google Scholar
• MCNEILL SA, DARUWALA PD, MITCHELL ID, SHEARER MG, HARGREAVE TB: Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled. BJU Int. (1999) 84(6):622-627.
   PubMedGoogle Scholar
• DJAVAN B, SHARIAT S, OMAR M: Does prolonged catheter drainage improve the chance of recovering voluntary voiding after acute urinary retention of urine(AUR)? Eur. Urol. (2003) 33(Suppl. 1):110.
   Google Scholar
• BUZELIN JM, HEBERT M, BLONDIN P: Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group. Br. J. Urol. (1993) 72(6):922-927.
   PubMedGoogle Scholar
• BUZELIN JM, FONTEYNE E, KONTTURI M, WITJES WP, KHAN A: Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. Br. J. Urol. (1997) 80(4):597-605.
   PubMedGoogle Scholar
• NORDLING J: Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int. (2005) 95(7):1006-1012.
   PubMed Web of Science ®Google Scholar
• DEBRUYNE FM, JARDIN A, COLLOI D et al.: Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur. Urol. (1998) 34(3):169-175.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION: The constitution of the World Health Organization. World Health Organ. Chron. (1947) 1:29.
   Google Scholar
• BERZON R, HAYS RD, SHUMAKER SA: International use, application and performance of health-related quality of life instruments. Qual. Life Res. (1993) 2:367.
   PubMed Web of Science ®Google Scholar
• ROSEN R, ALTWEIN J, BOYLE P et al.: Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur. Urol. (2003) 44(6):637-649.
   PubMed Web of Science ®Google Scholar
• VALLANCIEN G, EMBERTON M, HARVING N, VAN MOORSELAAR RJ: Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J. Urol. (2003) 169(6):2257-2261.
   PubMed Web of Science ®Google Scholar
• NICKEL JC, ELHILALI M, VALLANCIEN G, FOR THE ALF-ONE STUDY GROUP: Benign prostatic hyperplasia (BPH) and prostatitis:prevalence of painful ejaculation in men with clinical BPH. BJU Int. (2005) 95:571-574.
   PubMed Web of Science ®Google Scholar
• LARSON TR: Current treatment options for benign prostatic hyperplasia and their impact on sexual function. Urology (2003) 61(4):692-698.
   PubMed Web of Science ®Google Scholar
• NARAYAN P, LEPOR H: Long-term, open-label, Phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology (2001) 57:466-470.
   Google Scholar
• NICKEL JC, FRADET Y, BOAKE RC et al.: Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). Can. Med. Assoc. J. (1996) 155:1251-1259.
   PubMed Web of Science ®Google Scholar
• KASSABIAN VS: Sexual function in patients treated for benign prostatic hyperplasia. Lancet (2003) 361:60-62.
   PubMed Web of Science ®Google Scholar
• VAN MOORSELAAR R, EMBERTON M, HARVING N et al.: Alfuzosin 10 mg once daily improves sexual function in men with LUTS and concomitant sexual dysfunction [Abstr.]. Eur. Urol. (2003) 1(Suppl. 2):74.
   Google Scholar
• ANON: Alfuzosin (Uroxatral)-Another alpha-1 blocker for benign prostatic hyperplasia. The Medical Letter (2004) 46(1173):1-2.
   Google Scholar
• Impact of BPH medical treatment on sexual function: Symposium; urogenital health: a new paradigm for male integrated core. XXth Congress of the European Association of Urology. Istanbul, Turkey (17 March 2005).
   Google Scholar
• BUZELIN JM, DELAUCHE CAVALLIER MC, MARTIN D, ANGEL I: Clinical uroselectivity: evidence from patients treated with slow release alfuzosin for symptomatic benign prostatic obstruction. Br. J. Urol. (1998) 81(4):655-656.
   PubMedGoogle Scholar
• WEINER DM, LOWE FC: Alfuzosin for the management of benign prostate hyperplasia. Expert Opin. Pharmacother. (2003) 4(11):2057-2063.
   PubMed Web of Science ®Google Scholar
• CHANG DF, CAMPBELL JR: Intraoperative floppy iris syndrome associated with tamsulosin. J. Cataract Refract. Surg. (2005) 31:664-673.
   PubMed Web of Science ®Google Scholar
• DESAGER JP, HARVENGT C, BIANCHETTI G, ROSENZWEIG P: The effect of cimetidine on the pharmacokinetics of single oral doses of alfuzosin. Int. J. Clin. Pharmacol. Ther. Toxicol. (1993) 31(11):568-571.
   PubMedGoogle Scholar
• BIANCHETTI G, PADOVANI P, COUPEZ JM et al.: Pharmacokinetic interaction between hydrochlorothiazide, atenolol and alfuzosin: a new antihypertensive drug. Acta Pharmacol. Toxicol. (1986) 59(Suppl. 5):197-205.
   Google Scholar
• WILDE MI, FITTON A, MCTAVISH D: Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs (1993) 45(3):410-429.
   PubMed Web of Science ®Google Scholar
• BRAUN MH, SOMMER F, HAUPT G, MATHERS MJ, REIFENRATH B, ENGELMANN UH: Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical ‘aging male’ symptoms? Results of the ‘Cologne Male Survey’. Eur. Urol. (2003) 44:588-594.
   PubMed Web of Science ®Google Scholar
• KLONER RA, JACKSON G, EMMICK JT et al.: Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J. Urol. (2004) 172(5 Pt 1):1935-1940.
   PubMed Web of Science ®Google Scholar
• YASSIN A, DIEDE H: Combination therapy: alpha1-adrenoceptor blockade and tadalafil in BPH population. European Society of Sexual Medicine (ESSM). Istanbul, Turkey (16 – 19 November 2003).
   Google Scholar
• HARTUNG R, MATZKIN H, ALCARAZ A et al.: Age, comorbidity and anthypertensive comedication do not affect cardiovascular tolerability of alfuzosin 10 mg once daily. J. Urol. (2006) 175(2):624-628.
   PubMedGoogle Scholar